These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation. Reischig T; Kacer M Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996 [TBL] [Abstract][Full Text] [Related]
12. CMV infection as a contributory factor for renal allograft injury and loss. Gerstenkorn C; Robertson H; Bell A; Shenton B; Talbot D Transplant Proc; 2001 Jun; 33(4):2461-2. PubMed ID: 11406211 [No Abstract] [Full Text] [Related]
13. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. Tilden DP; Chapman J; Davey PJ; Solly ML; Crowley S Clin Transplant; 2004 Jun; 18(3):312-20. PubMed ID: 15142054 [TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic analysis of preemptive gancyclovir therapy in the prevention of cytomegalovirus infections in high-risk renal graft recipients. Chak WL; Choi KS; Wong KM; Chan YH; Chau KF; Li CS Transplant Proc; 2003 Feb; 35(1):280-1. PubMed ID: 12591399 [No Abstract] [Full Text] [Related]
15. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. Jassal SV; Roscoe JM; Zaltzman JS; Mazzulli T; Krajden M; Gadawski M; Cattran DC; Cardella CJ; Albert SE; Cole EH J Am Soc Nephrol; 1998 Sep; 9(9):1697-708. PubMed ID: 9727379 [TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limits. Bertoni E; Rosati A; Zanazzi M; Moscarelli L; Di Maria L; Piperno R; Orsi A; Parri F; Dedola G; Salvadori M Transplant Proc; 1998 Aug; 30(5):2094. PubMed ID: 9723402 [No Abstract] [Full Text] [Related]
17. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354 [TBL] [Abstract][Full Text] [Related]
19. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. Kacer M; Kielberger L; Bouda M; Reischig T Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586 [TBL] [Abstract][Full Text] [Related]
20. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]